Goldman Sachs
ALXO icon

Goldman Sachs’s ALX Oncology ALXO Stock Holding History

Goldman Sachs’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$278K Buy
138,593
+121,331
+703% +$231K ﹤0.01% 5933
2025
Q4 		$19.5K Sell
17,262
-1,332
-7% -$2.02K ﹤0.01% 6344
2025
Q3 		$34K Sell
18,594
-271,099
-94% -$235K ﹤0.01% 6206
2025
Q2 		$120K Sell
289,693
-83,521
-22% -$42.2K ﹤0.01% 5782
2025
Q1 		$233K Sell
373,214
-195,795
-34% -$235K ﹤0.01% 5573
2024
Q4 		$950K Buy
569,009
+312,130
+122% +$480K ﹤0.01% 4855
2024
Q3 		$468K Buy
256,879
+41,627
+19% +$155K ﹤0.01% 5087
2024
Q2 		$1.3M Buy
215,252
+58,250
+37% +$716K ﹤0.01% 4272
2024
Q1 		$1.75M Buy
157,002
+66,259
+73% +$931K ﹤0.01% 3956
2023
Q4 		$1.35M Sell
90,743
-40,384
-31% -$383K ﹤0.01% 4210
2023
Q3 		$629K Sell
131,127
-48,640
-27% -$264K ﹤0.01% 4538
2023
Q2 		$1.35M Sell
179,767
-880
-0.5% -$5.76K ﹤0.01% 4141
2023
Q1 		$817K Buy
180,647
+5,186
+3% +$39.3K ﹤0.01% 4529
2022
Q4 		$1.98M Buy
175,461
+14,715
+9% +$165K ﹤0.01% 3953
2022
Q3 		$1.54M Sell
160,746
-86,997
-35% -$1.01M ﹤0.01% 4193
2022
Q2 		$2M Buy
247,743
+33,257
+16% +$362K ﹤0.01% 4057
2022
Q1 		$3.63M Buy
214,486
+75,348
+54% +$1.29M ﹤0.01% 3648
2021
Q4 		$2.99M Sell
139,138
-23,858
-15% -$1.03M ﹤0.01% 3888
2021
Q3 		$12M Buy
162,996
+26,663
+20% +$1.78M ﹤0.01% 2538
2021
Q2 		$7.46M Sell
136,333
-117,052
-46% -$7M ﹤0.01% 2980
2021
Q1 		$18.7M Buy
253,385
+121,757
+93% +$9.58M ﹤0.01% 1994
2020
Q4 		$11.3M Buy
131,628
+124,247
+1,683% +$7.47M ﹤0.01% 2355
2020
Q3 		$279K Buy
+7,381
New +$290K ﹤0.01% 4773

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Goldman Sachs's ALXO Position: Q1 2026 in Review

Goldman Sachs increased its ALX Oncology (ALXO) stake by 703% in Q1 2026, buying an estimated $231K and bringing the position to 138,593 shares worth $278K. The position accounts for ﹤0.01% of the portfolio, ranked #5933.

Goldman Sachs first reported a position in ALXO in Q3 2020 and has held it in 23 quarters since. The position peaked at $18.7M in Q1 2021. 69 funds tracked by Wall St. Rank hold ALXO as of Q1 2026.

  • Goldman Sachs held 138,593 shares of ALX Oncology worth $278K as of Q1 2026.
  • Goldman Sachs bought 121,331 ALX Oncology shares in Q1 2026, an estimated $231K.
  • ALX Oncology made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5933 holding.
  • Goldman Sachs first reported a position in ALX Oncology in Q3 2020 and has held it in 23 quarters since.
  • Goldman Sachs's ALX Oncology position peaked at $18.7M in Q1 2021.
  • 69 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.